Comparative Effectiveness and Safety of Polymer-Free Biolimus-Eluting Stent and Durable Polymer Everolimus-Eluting Stent in All-Comer Patients Who Underwent Percutaneous Coronary Interventions
| Autor: | Francesco Prati, Giuseppe Biondi-Zoccai, Nicola Corcione, Sirio Conte, Arturo Giordano, Martino Pepe, Alberto Morello, Francesco Paolo Bianchi, Paolo Ferraro, Alessandro Santo Bortone, Palma Luisa Nestola |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Percutaneous medicine.medical_treatment Population Myocardial Infarction 030204 cardiovascular system & hematology Prosthesis Design 03 medical and health sciences Percutaneous Coronary Intervention 0302 clinical medicine Restenosis Internal medicine Absorbable Implants Humans Medicine Everolimus Prospective Studies 030212 general & internal medicine Myocardial infarction education Prospective cohort study Aged Sirolimus education.field_of_study business.industry Stent Percutaneous coronary intervention Drug-Eluting Stents Middle Aged medicine.disease Surgery Treatment Outcome Cohort Cardiology Female Cardiology and Cardiovascular Medicine business Immunosuppressive Agents Follow-Up Studies |
| Zdroj: | The American Journal of Cardiology. 124:195-204 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2019.04.015 |
| Popis: | We aim to compare Polymer-Free Biolimus-Eluting Stent (PF-BES) with Durable Polymer Everolimus-Eluting stent (DP-EES) in unselected patients. PF-BES showed a favorable profile in high-bleeding risk patients who underwent percutaneous coronary intervention. Limited data are available on PF-BES compared with second-generation durable polymer-coated drug-eluting stents in patients eligible for standard dual antiplatelet therapy. A total of 848 consecutive patients were enrolled: 306 patients were treated with PF-BES and 542 with DP-EES. Stent performance was tested in a propensity score-matched population and in a Complex Higher-Risk and Indicated Patients (CHIP) subpopulation. A per-lesion analysis on 1,204 lesions (PF-BES = 424 vs DP-EES = 780) was also performed. At a medium follow-up of 18.5 ± 5.0 months, no differences in the matched population were found in terms of major adverse cardiac events (PF-BES 9.0% vs DP-EES 4.5%; p 0.091), myocardial infarction (PF-BES 6.2% vs DP-EES 2.3%; p 0.111), stent restenosis (PF-BES 2.3% vs DP-EES 0.0%; p 0.123), definite or probable stent thrombosis (PF-BES 2.8% vs DP-EES 1.1%; p 0.448). A significant inferior rate of restenosis was observed in the DP-EES arm in the whole (PF-BES 2.3% vs DP-EES 0.6%; p 0.041) and CHIP populations (PF-BES 4.3% vs DP-EES 0.5%; p 0.023), as well as in the per-lesion analysis (DP-EES 0.4% vs PF-BES 1.7%; p 0.039). In conclusion, in a real-world cohort PF-BES performed similarly to DP-EES in terms of restenosis and stent thrombosis in the matched population. Nonetheless, in the whole and CHIP populations, as well as in the per-lesion analysis, restenosis occurrence resulted higher in the PF-BES group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect